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ORIGINAL ARTICLE
Nectin-4: a new prognostic biomarker for efficient
5 therapeutic targeting of primary and metastatic
triple-negative breast cancer
M. M-Rabet1, O. Cabaud2, E. Josselin3, P. Finetti2, R. Castellano3, A. Farina4, E. Agavnian-Couquiaud4,
10 G. Saviane2, Y. Collette3, P. Viens5, A. Gonçalves5, C. Ginestier2, E. Charafe-Jauffret2, D. Birnbaum2,
D. Olive1, F. Bertucci2,5*† & M. Lopez2†AQ1
1Equipe Immunité et Cancer; 2Equipe Oncologie Moléculaire; 3TrGET Platform; 4ICEP Platform, Inserm, U1068, CRCM, Institut Paoli Calmettes, Aix-Marseille
Université, UM 105, CNRS, UMR7258, Marseille; 5Département d’Oncologie Médicale, Institut Paoli Calmettes, Aix-Marseille Université, UM 105, Marseille, FranceAQ2
15 *Correspondence to: Prof. François Bertucci, Department of Medical Oncology, Institut Paoli-Calmettes, 232 Bd. Sainte-Marguerite, 13009 Marseille, France.
Tel: þ33-4-91-22-35-37; Fax: þ33-4-91-22-36-70; E-mail: bertuccif@ipc.unicancer.fr
†Both authors contributed equally as senior authors.
Background: Triple-negative breast cancers (TNBCs) are associated withAQ3 a poor prognosis. In contrast to other molecular sub-
20 types, they have no identified specific target and chemotherapy remains the only available systemic treatment. The adhesion
molecule nectin-4AQ4 represents a new potential therapeutic target in different cancer models. Here, we have tested the prognos-
tic value of nectin-4 expression and assessedAQ5 the therapeutic efficiency of an anti-nectin 4 antibody drug conjugate (ADC) on
localised and metastatic TNBC in vitro and in vivo.AQ6
Materials and methods: We analysed nectin-4/PVRL4 mRNA expression in 5673 invasive breast cancers and searched for
25 correlations with clinicopathological features including metastasis-free survival (MFS). Immunohistochemistry was carried out
in 61 TNBCs and in samples of primary TNBC Patient-Derived Xenografts (PDXs). An anti-nectin-4 antibody eligible for ADC was
produced and tested in vitro and in vivo in localised and metastatic TNBC PDXs.
Results: High nectin-4/PVRL4 mRNA expression was associated with poor-prognosis features including the TN and basal sub-
types. High PVRL4 mRNA expression showed independent negative prognostic value for MFS in multivariate analysis in TNBCs.
30 Nectin-4 protein expression was not detected in adult healthy tissues including mammary tissue. Membranous protein expres-
sion was found in 62% of TNBCs, with strong correlation with mRNA expression. We developed an ADC (N41mab-vcMMAE)
comprising a human anti-nectin-4 monoclonal antibody conjugated to monomethyl auristatin-E (MMAE). In vitro, this ADC
bound to nectin-4 with high affinity and specificity and induced its internalisation as well as dose-dependent cytotoxicity on
nectin-4-expressing breast cancer cell lines. In vivo, this ADC induced rapid, complete and durable responses on nectin-4-
35 positive xenograft TNBC samples including primary tumours, metastatic lesions, and local relapses; efficiency was dependent
on both the dose and the nectin-4 tumour expression level.
Conclusion: Nectin-4 is both a new promising prognostic biomarker and specific therapeutic target for ADC in the very lim-
ited armamentarium against TNBC.
Key words: ADC targeting, biomarker, breast cancer, nectin-4, survival, TNBC
40 Introduction
Triple-negative breast cancers (TNBCs) represent about 15–20%
of breast cancers, and are characterised by the absence of expres-
sion of oestrogen and progesterone receptors and the absence of
HER2 overexpression or gene amplification. They show overlap-
45ping genomic characteristics with basal BCs [1–3]. Patients with
TNBC have a higher risk of early and visceral relapse than patients
with non-TN breast cancer [4]. However, despite recent efforts to
find alternative treatments such as hormone therapy and anti-
VC The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
All rights reserved. For permissions, please email: journals.permissions@oup.com.
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HER2 drugs for, respectively, hormone receptor-positive and
HER2-positive breast cancers, there are no efficient targeted
therapies for TNBCs and chemotherapy remains the only avail-
able systemic treatment [5]. A cell surface protein specifically ex-
5 pressed in TNBC malignant cells and not in normal breast would
consequently represent an ideal molecular surface biomarker as
well as a potential therapeutic target for antibody–drug conjugate
(ADC).
ADCs are monoclonal antibodies conjugated to cytotoxic
10 agents. Antibodies are specific to tumour cell-surface proteins,
and thus, have tumour specificity and potency not achievable
with traditional drugs [6]. Design of effective ADC for cancer
therapy requires the identification of an appropriate target, a
monoclonal antibody against the target, potent cytotoxic effector
15 molecules, and conjugation of the monoclonal antibody to cyto-
toxic agents. Two ADCs recently received approval from the US
Food and Drug Administration for treatment of CD30-positive
lymphoma (brentuximab-vedotin) and HER2-positive breast
cancer (trastuzumab-emtansine), and several new promising
20 ADCs are now in late-phase clinical testing [6, 7].
PVRL4/Nectin-4 is involved in the formation and maintenance
of adherens junctions in cooperation with cadherins [8–10].
Nectin-4 is a type I transmembrane cell adhesion molecule com-
posed of three Ig-like domains (V–C–C type) in its extracellular
25 region [8]. It is also a receptor for the measles virus, mediating its
endocytosis [11]. Nectin-4 is expressed during foetal develop-
ment, with expression declining in adult life by contrast with the
extensive expression of the other nectins in adult tissues [8]. We
and others have shown that nectin-4 is re-expressed as a tumour-
30 associated antigen with pro-oncogenic properties in various car-
cinomas including breast cancer [12–17]. These features associ-
ated with its limited expression in the respective normal tissues,
suggest that nectin-4 could be a therapeutic target for ADC in
these cancers, as recently reported in bladder, breast and pancre-
35 atic cancers [17].
Here, we have analysed the mRNA and protein expression of
nectin-4 in a series of 5700 breast cancers and showed that
nectin-4 was a cell surface biomarker more frequently overex-
pressed in TNBCs and basal breast cancers, and that high mRNA
40 expression was an independent poor-prognosis factor in TNBCs.
Then, we have developed an anti-nectin-4 ADC and showed its
therapeutic efficiency on localised and metastatic TNBC both
in vitro and in vivo, with rapid, complete, and long-lasting regres-
sion in nectin-4-positive patient samples.
45 Materials and methods
Patients and breast cancer samples
The clinical samples had been profiled using DNA microarrays for gene
expression analyses. Our own data set included 353 cases representing
pre-treatment invasive carcinomas from patients non-metastatic at diag-
50 nosis. The study was approved by our institutional review board (IRB
agreement no. 15-002). Each patient gave a written informed consent for
research use. We pooled our series with 17 publicly available data sets
comprising at least one probe set representing PVRL4/nectin-4. These
sets were collected from the National Center for Biotechnology
55 Information (NCBI)/Genbank GEO and ArrayExpress databases, and au-
thors’ website (supplementary Table S1, available at Annals of Oncology
online). The final pooled set included 5673 non-redundant, non-meta-
static, non-inflammatory, primary, invasive breast cancers with PVRL4
mRNA expression and clinicopathological data available (supplementary
60Table S2, available at Annals of Oncology online).
For protein expression, we analysed a consecutive series of 61 previ-
ously untreated TNBC samples collected at the time of diagnosis from
women treated at our Institute. Informed consent was obtained for each
patient and the study was approved by our IRB (supplementary Table S3,
65available at Annals of Oncology online).
MDA-MB-231 and SUM190 breast cancer cell lines were used in this
study. Detailed information is available in supplementary Methods
(available at Annals of Oncology online).
Gene expression data analysis
70Our own gene expression data set had been generated using Affymetrix
U133 Plus 2.0 human microarrays (Affymetrix
VR
, Santa Clara, CA) as
described [18]. MIAME-compliant data are deposited in the GEO data-
base (GSE31448). PVRL4 expression was measured by analysing different
probe sets whose identity and specificity were verified using the NCBI
75program BLASTN 2.2.31þ (supplementary Table S4, available at Annals
of Oncology online). Additional details are available in supplementary
Methods (available at Annals of Oncology online).
Antibody production, immunohistochemistry,
western-blot, ELISA and flow cytometry
80Different nectin-4 antibodies were produced. Detailed information is
available in supplementary Methods (available at Annals of Oncology
online).
Production of ADC
The ADC was produced by Concortis (San Diego, CA). Conjugates were
85produced from purified mab1/N41mab monoclonal antibody. The linker
used was the maleimidocaproyl-L-valine-L-citrulline-p-aminobenzyl al-
cohol p-nitrophenyl carbonate (MC-Val-Cit-PAB-PNP) covalently con-
jugated to monomethyl auristatin-E (MMAE). This cleavable linker was
selected because it induced potent bystander killing. The drug-to-
90antibody ratio was 4.73.
Animal models
All experiments were done in agreement with the French Guidelines for
animal handling and approved by local ethics committee (Agreement no.
01152-01). Additional details are available in supplementary Methods
95(available at Annals of Oncology online).
Statistical analysis
This section is detailed in supplementary Methods (available at Annals of
Oncology online).
Results
100Nectin-4/PVRL4 is expressed in TNBC and predicts
poor prognosis
We examined PVRL4 expression in breast cancer. Whole-
genome clustering of our 353-sample series showed that PVRL4
mRNA was in the ‘basal’ gene cluster and more consistently
105expressed in basal tumours (Figure 1A and B). We analysed
nectin-4 protein expression by immunohistochemistry in 61
TNBCs, 12 of them previously profiled using DNA microarrays.
Original article Annals of Oncology
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The monoclonal antibody used for this analysis, selected from our
screening (see next paragraph), recognised the distal IgV-like do-
main of human nectin-4 and did not cross-react with the other
human nectins or with mouse nectin-4 (supplementary Figure S1,
5 available at Annals of Oncology online). Nectin-4 expression was
detected at the plasma membrane. Based on the QuickScore (QS)
semi-quantitative assessment, we distinguished a ‘nectin-4-high
group’ (QS> 100) and a ‘nectin-4-low group’ (QS 100), repre-
senting 62% and 38% of TNBCs, respectively (Figure 1C). There
10was a positive correlation between mRNA and protein expression
of nectin-4 (supplementary Figure S2, available at Annals of
Oncology online; P¼ 0.002). Importantly, nectin-4 was detected
neither in the normal mammary gland epithelium (Figure 1D) nor
in 30 different adult normal tissues except the skin (supplementary
E
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Figure 1. PVRL4/nectin-4 expression in clinical breast cancer samples. (A) Hierarchical clustering of 353 primary breast cancer samples and 12 304 genes based on mRNA expression levels.
Each row represents a gene and each column represents a sample. The dendrogram of samples is zoomed in (B). Coloured bars to the left indicate the locations of five gene clusters of interest.
(B) Expanded view of the ‘basal’ gene cluster, which includes the PVRL4 gene. (C) Nectin-4 expression in TNBCs by IHC on frozen sections using 0.5 mg/ml mab1/N41mab. Staining is promin-
ent at the plasma membrane.AQ10 T1 and T2 are two TNBCs with QS> 100. T3 and T4 are two TNBCs with QS< 100. Nectin-4 expression is rare in HRþ and HER2þ breast tumours in accord-
ance with mRNA expression (data not shown). Scale bar: 100 lm. (D) Absence of expression in the normal human epithelial mammary gland tissue. Scale bar: 100 lm. (E) Kaplan–Meier
MFS curves according to PVRL4 mRNA expression in TNBCs (n¼290).
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Figure S3, available at Annals of Oncology online) [10]. These re-
sults established nectin-4 as both a new cell surface biomarker and
a potential target for TNBCs.
We then analysed a pooled series of 5673 invasive breast can-
5 cers profiled using DNA microarrays and five different PVRL4
probes 100% specific. High PVRL4 expression was associated
with poor-prognosis features, including both TN and basal sub-
types (supplementary Table S5, available at Annals of Oncology
online). PVRL4 was highly expressed in 61% of TN samples and
10 62% of basal samples versus 47% of non-TN or non-basal sam-
ples. Metastasis-free survival (MFS) data were available for 1037
patients, including 613 without metastatic relapse (median
follow-up, 83 months) and 424 with metastatic relapse (median
time to relapse, 24 months). The 5-year MFS rate was 61% (95
15 %CI, 0.58–0.65). In the whole population, high PVRL4 expres-
sion was associated with shorter MFS (P¼ 0.014, log-rank test)
(supplementary Figure S4, available at Annals of Oncology on-
line). Prognostic univariate analysis per molecular subtype
showed that high PVRL4 expression was associated with MFS in
20 the TN subtype only, with 5-year MFS of 47% (95%CI, 0.40–0.
55) versus 62% (95%CI, 0.51–0.74) in the ‘PVRL4-high’ and
‘PVRL4-low’ groups, respectively (P¼ 0.014, log-rank test)
(Figure 1E, available at Annals of Oncology online). In multivari-
ate analysis (Table 1), high PVRL4 expression remained signifi-
25 cant (P¼ 0.039, Wald test; HR¼ 1.53 [1.02–2.30]). Altogether,
these results indicated that PVRL4/nectin-4 is commonly ex-
pressed in TN or basal breast cancers, not expressed in the normal
breast, and is an independent predictor of shorter MFS in
TNBCs.
30 ADC-based targeting of nectin-4 in vitro
We tested six monoclonal antibodies (mAbs) directed against the
IgV-like distal domain of nectin-4 to isolate a mAb able to induce
internalisation. MAbs were evaluated for EC50, maximum bind-
ing capacity, cell surface internalisation and cytotoxicity (supple
35 mentary Figure S5, available at Annals of Oncology online).
Internalisation was tested using ectopically expressed Flag-tagged
nectin-4 expressed in MDA-MB-231 cells and FITC-labelled
anti-Flag antibody (M2, Sigma-Aldrich, St. Louis, MO) to quan-
tify residual surface nectin-4. Mab1 was the most efficient
40antibody. It induced a 60% decrease of cell surface nectin-4 in
24 h and a 60% cell growth inhibition after incubation with a goat
anti-mouse monoclonal antibody conjugated to saporin (mab-
ZAP kit, ATS-bio, San Diego, CA). Internalisation and cytotox-
icity were positively correlated (R2¼0.96). Mab1 did not affect
45cell viability in vitro and tumour cell growth in vivo (data not
shown). Mab1 was then conjugated to monomethyl auristatin-E
(MMAE) via a cleavable valine-citrulline (vc) di-peptide linker
(thereafter called N41mab-vcMMAE, ADC) to produce an ADC,
which was then tested in vitro for specificity and efficacy on se-
50lected breast cancer cell lines. MDA-MB-231 cells, which express
nectin-1, nectin-2, and nectin-3, but not nectin-4, were not sensi-
tive to the ADC. However, ectopic expression of nectin-4 con-
ferred sensitivity with an IC50¼ 2 ng/ml (supplementary Figure
S6A, available at Annals of Oncology online). SUM190 cells, which
55express endogenous nectin-4, were sensitive with an IC50¼ 4 ng/
ml (supplementary Figure S6B, available at Annals of Oncology
online). These data showed the specificity and the efficacy of
N41mab-vcMMAE.
ADC-based targeting of nectin-4 in vivo
60Activity of our ADC was tested in three in vivo models of TNBC
developed in immunocompromised NSG mice. First, mice xeno-
grafted with SUM190 cells were treated with two successive i.v.
doses of N41mab-vcMMAE (Figure 2A). These doses were not
toxic for mice (supplementary Figure S7, available at Annals of
65Oncology online). N41mab-vcMMAE induced a rapid (4 days)
and complete tumour regression, the duration of which was
dose-dependent and lasted up to 40 days at the 10 mg/kg dose
(Figure 2A). Interestingly, after relapse, tumours still kept their
sensitivity to the ADC with tumour regression similar to that ob-
70tained after the first treatment, at least over a 6-months period
(Figure 2B).
Second, we used patient-derived xenografts (PDX) of nine pri-
mary TNBCs. These pre-clinical models recapitulate breast can-
cer physiopathology [19]. Localisation and levels of nectin-4
75expression in PDX were similar to that found in TNBC patients
(supplementary Figure S8, available at Annals of Oncology on-
line). Nectin-4 expression was prominently found at the plasma
membrane in seven of nine PDX (QS> 100). TNBC PDX mice
Table 1. Univariate and multivariate prognostic analyses in the TNBC population
Characteristics Univariate Multivariate
n HR [95%CI] P-value n HR [95%CI] P-value
Age, >50 versus<¼50 204 1.13 [0.68–1.89] 0.63
Pathological type, lobular versus ductal 128 1.49 [0.36–6.24] 0.28
Pathological type, mixed versus ductal 0.00 [0.00–Inf.]
Pathological type, other versus IDC 0.38 [0.13–1.07]
Pathological tumour size (pT), pT2–3 versus pT1 107 1.39 [0.56–3.41] 0.48
Pathological lymph node status (pN), positive versus negative 202 0.75 [0.49–1.15] 0.19
Pathological grade, 3 versus 1–2 219 1.42 [0.72–2.78] 0.31
Immune response GES, poor versus good 290 1.82 [1.19–2.80] 6.08E03 290 1.13 [0.54–2.38] 0.740
LCK GES, poor versus good 290 1.92 [1.34–2.76] 3.80E04 290 1.55 [1.03–2.35] 3.67E02
Kinase immune GES, poor versus good 290 1.82 [1.23–2.63] 2.33E03 290 0.77 [0.40–1.49] 0.439
PVRL4/nectin-4 mRNA expression, high versus low 290 1.65 [1.10–2.47] 1.54E02 290 1.53 [1.02–2.30] 3.95E02
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Figure 2. In vivo efficacy of the ADC N41mab-vcMMAE in TNBC models. (A) SUM190 cells grown orthotopically as tumours in NSG mice show dose-dependent regression after a single
treatment with ADC at the indicated doses (2 i.v. injections (arrows) at 4-days interval). (B) Similar to (A). First arrows: first treatment by 2 i.v. injections at 10 mg/kg; second and third
arrows: same treatment at second and third relapses. Tumour regression kinetic after relapse is similar to regression observed after the first treatment. (C–F) TN patient-derived tumour grown
orthotopically in NSG mice and treated with ADC at 10 mg/kg (2 i.v. injections at 4-days interval). (C) PDX400 (QS¼ 3 100%); (D) PDX317 (QS¼ 2 70%); (E) PDX348
(QS¼ 2 50%); (F) PDX434 (QS¼ 1 10%). A bystander effect, described for cleavable linkers, may account for the inhibition observed for T317 and T348. (G) Docetaxel treatment
(10 mg/kg) of PDX348. Arrows indicate i.v. injection. Error bars represent mean 6 SEM.
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with different QS were treated with two successive i.v. doses of
ADC. The degree of clinical response was roughly correlated with
nectin-4 expression level: a rapid and complete tumour burden
regression (and durable up to 35 days) was observed for PDX400
5 (QS¼ 300) and PDX 317 (QS¼ 140), to a lesser extent for
PDX348 (QS¼ 100) (Figure 2C–E), but not observed for
PDX434 (QS¼ 10) (Figure 2F). In contrast, treatment of PDX
348—sensitive to our ADC—by docetaxel (3 times 10 mg/kg i.p.)
was ineffective (Figure 2G).
10 Third, to evaluate ADC treatment efficacy in a more advanced
disease, we treated PDX400 and PDX317 mice developing spon-
taneous metastatic lesions from primary tumours. In both cases,
treatment with two successive i.v. doses of ADC led to a rapid re-
duction and complete disappearance of all metastatic lesions
15 observed by luminescence analysis (Figure 3). Metastatic recur-
rences were detected at days 42 and 57 for PDX400, and still not
observed for PDX317 (ongoing experiment: day 245) (data not
shown). These results showed that N4mab1-vcMMAE had a
marked anti-tumour activity in both primary and metastatic
20 nectin-4-expressing TNBCs.
discussion
Nectin-4 has been reported as a new tumour antigen for different
carcinomas [12–17]. Here, we have analysed its mRNA and pro-
tein expression in a series of 5700 breast cancers and showed
25 that nectin-4 was a cell surface biomarker more frequently over-
expressed in TNBCs and basal breast cancers, and that high
mRNA expression was an independent poor-prognosis factor for
MFS in TNBCs. Then, we have developed an anti-nectin-4 ADC
and showed its therapeutical efficiency on localised and meta-
30static TNBC both in vitro and in vivo, with rapid and long-lasting
regression in nectin-4-positive samples. To our knowledge, this
work is the first description of a cell surface biomarker eligible for
the systemic treatment of TNBCs.
We showed that nectin-4 is a cell surface biomarker more fre-
35quently overexpressed in TNBCs and basal breast cancers. Its pro-
tein expression, analysed by immunohistochemistry (IHC) using
our antibody, was detected at the plasma membrane and posi-
tively correlated with mRNA expression. High-protein expres-
sion and high mRNA expression were found in the same
40proportion of cases, nearly two-thirds of TNBCs. This protein ex-
pression pattern was confirmed using four other monoclonal
antibodies recognising different epitopes in the nectin-4 ectodo-
main (supplementary Figure S9, available at Annals of Oncology
online). Importantly, nectin-4 protein was not detected in the
45normal mammary gland epithelium and 30 other different adult
normal tissues except the skin. These results confirmed and ex-
tended our previous work done within a limited number of sam-
ples [12] (Figure 1). To our knowledge, nectin-4 expression has
been studied in clinical breast cancer samples in three other stud-
50ies using IHC in two series of 197 [20] and 654 [17] cases and
using immunocytochemistry in a series of imprint smears of 140
cases [21]. Two studies used the same commercial polyclonal
antibody [20, 21]. We tested this antibody on nectin-4 mRNA
negative TNBCs and found a cytoplasmic and a nuclear staining
55by IHC (data not shown). This polyclonal antibody recognised
nectin-4 by western-blot but, in contrast to N41mab, gave a high
background signal on nectin-4 mRNA negative MDA-MB-231
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Figure 3. N41mab-vcMMAE treatment of PDX400 and PDX317 mice impacts spontaneous metastatic progression. After surgical resection of primary mammary tumours, spontaneous me-
tastasis occurrence was followed by bioluminescence imaging. Metastatic mice were treated vehicle (left, A, B and C) or with N41mab-vc-MMAE (right, D, E and F) by caudal i.v. injection.
Quantification of total bioluminescence signal was measured. Major metastatic localisations observed at autopsy were as follows: PDX400 (A): liver, lymph node, lung; PDX400 (B): liver, lymph
node, ovary; PDX400 (D): interscapular mass, lung; PDX400 (E): liver, pancreas; PDX317 (C and F): lung, heart.
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cells (supplementary Figure 1B, available at Annals of Oncology
online). In the third study, authors generated their own mono-
clonal antibody, directed against the extra-cellular domain of
human nectin-4, and analysed 654 breast cancers (primary tu-
5 mours and metastases): 53% of specimens showed moderate to
strong staining, but no correlation with clinicopathological fea-
tures or survival was looked for. In our series, high nectin-4 ex-
pression was an independent poor-prognosis factor for MFS in
the TNBC patients only. Interestingly, we observed that nectin-4
10 overexpression increased tumour growth and metastasis forma-
tion in mouse xenograft models (data not shown). De novo ex-
pression of nectin-4 may perturb nectin-supported adherens
junctions and increase cell migration.
Nectin-4 presents two interesting properties: an inducible and
15 efficient internalisation, which is hijacked by the measles virus,
and a limited expression in healthy tissues. Together, these prop-
erties make nectin-4 an attractive target for the development of
immune-base therapies especially for TNBCs for which no spe-
cific cell surface antigen has been identified so far [22]. ADC dir-
20 ected against nectin-4 has been recently shown efficient in mice
models subcutaneously xenografted with cell lines [17]. Based on
in vitro assessment of EC50, maximum binding capacity, cell sur-
face internalisation and cytotoxicity, we retained the Mab1 for
ADC approach. Mab1 was then conjugated to monomethyl
25 auristatin-E (MMAE) via a cleavable linker to produce an ADC,
thereafter called N41mab-vcMMAE. This ADC was validated
in vitro for efficiency and specificity.
We then showed its in vivo activity in models of TNBC de-
veloped in immunocompromised NSG mice. The model based
30 on the SUM190 cell line exhibited rapid and complete response,
the duration of which was prolonged and dependent on the dose;
furthermore, the relapses remained similarly sensitive to our
ADC over the 6-months period tested. We also took advantage of
our collection of primary TNBC PDXs phenotypically close to
35 the physiopathology of TNBCs [19]. In these models, patient tu-
mours develop in the mouse mammary gland and spontaneously
spread to the same sites as do metastatic TNBCs (Figure 3). High
expression of nectin-4 was found in two-thirds of PDXs, a pro-
portion close to that observed in our clinical series. The results
40 showed a marked efficiency of the anti-nectin-4 ADC with com-
plete and durable eradication of both localised TNBC tumours
and metastatic lesions of different sites. These data not only con-
firmed the results previously reported [17] with another anti-
nectin-4 ADC (AGS-22M6E) but also showed additional import-
45 ant results. Our ADC induced complete and durable responses
on both primary tumours, metastatic lesions and local relapses,
and the degree of response was dependent on the nectin-4 tu-
mour expression level. We surmise that tumour shrinkage is due
to toxin delivery because N41mab without drug did not have in-
50 trinsic anti-tumour growth activity both in vitro and in vivo. In
vivo pre-clinical responses with N41mab-vcMMAE were
observed for ‘nectin-4-high’ TN tumours (QS> 100), predicting
a good response in most TNBC patients (62% of cases). We also
found similar efficacy between N41mab conjugated to emtansine
55 (N41mab-DM1) and trastuzumab-DM1 [23] in SUM190-
xenografted mice (data not shown). Because both nectin-4 and
HER2 are equally expressed at the surface of SUM190 cells, we
can postulate that nectin-4-based ADC is at least as efficient as
trastuzumab-DM1 in this model.
60Efficacy of drugs used for treatment in humans is closely de-
pendent on the toxicity they induce in healthy tissues. This is also
true for ADC-based therapy where expression of the target has to
be restricted to the malignant cells. Consequently, the restricted
expression pattern of nectin-4 in humans would predict a limited
65toxicity. The ADC tested here did not induce any toxicity in mice
even after repeated treatments. However, this cannot predict an
absence of toxicity in humans because our N41mab does not
cross-react with murine nectin-4. A phase I study addressing this
issue was recently completed for examining the safety of AGS-
7022M6E ADC as monotherapy in patients with malignant solid tu-
mours expressing nectin-4 (Clinical Trials.gov Identifier,
NCT01409135). Another ongoing phase I study is assessing the
safety and pharmacokinetics of escalating doses of ASG-22CE
given as monotherapy in subjects with metastatic urothelial can-
75cer and other malignant solid tumours that express nectin-4
(Clinical Trials.gov Identifier, NCT02091999).
In conclusion, we show that nectin-4 is a new promising thera-
peutic target in the armamentarium against TNBC. It is a cell sur-
face biomarker frequently expressed in TNBCs, with independent
80negative prognostic value, and without expression in normal
breast tissue. The anti-nectin 4 ADC that we developed
(N41mab-vcMMAE) induced complete and durable responses
in vitro and in vivo on nectin-4-positive samples including pri-
mary tumours, metastatic lesions and local relapses; efficiency
85was dependent on both the dose and the nectin-4 tumour expres-
sion level. Evaluation of this ADC in the clinical setting is war-
ranted. Additionally, because resistance to auristatin-based ADC
has been reported [24], we are currently developing in vivo mod-
els aiming to evaluate tumour resistance to our ADC.
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Key Message
We show that high nectin-4 expression was associated with triple-negative breast cancers with independent negative prognostic value.
Nectin-4 was not detected in healthy tissues. We developed an ADC comprising a human anti-nectin-4 monoclonal antibody conju-
gated to MMAE that induced complete and durable responses of primary tumours, metastases and local relapses in nectin-4-positive
xenograft TNBC samples.AQ7
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